Mazuski John E, Tessier Jeffrey M, May Addison K, Sawyer Robert G, Nadler Evan P, Rosengart Matthew R, Chang Phillip K, O'Neill Patrick J, Mollen Kevin P, Huston Jared M, Diaz Jose J, Prince Jose M
1 Department of Surgery, Washington University School of Medicine , Saint Louis, Missouri.
2 JPS Health System , Fort Worth, Texas.
Surg Infect (Larchmt). 2017 Jan;18(1):1-76. doi: 10.1089/sur.2016.261.
Previous evidence-based guidelines on the management of intra-abdominal infection (IAI) were published by the Surgical Infection Society (SIS) in 1992, 2002, and 2010. At the time the most recent guideline was released, the plan was to update the guideline every five years to ensure the timeliness and appropriateness of the recommendations.
Based on the previous guidelines, the task force outlined a number of topics related to the treatment of patients with IAI and then developed key questions on these various topics. All questions were approached using general and specific literature searches, focusing on articles and other information published since 2008. These publications and additional materials published before 2008 were reviewed by the task force as a whole or by individual subgroups as to relevance to individual questions. Recommendations were developed by a process of iterative consensus, with all task force members voting to accept or reject each recommendation. Grading was based on the GRADE (Grades of Recommendation Assessment, Development, and Evaluation) system; the quality of the evidence was graded as high, moderate, or weak, and the strength of the recommendation was graded as strong or weak. Review of the document was performed by members of the SIS who were not on the task force. After responses were made to all critiques, the document was approved as an official guideline of the SIS by the Executive Council.
This guideline summarizes the current recommendations developed by the task force on the treatment of patients who have IAI. Evidence-based recommendations have been made regarding risk assessment in individual patients; source control; the timing, selection, and duration of antimicrobial therapy; and suggested approaches to patients who fail initial therapy. Additional recommendations related to the treatment of pediatric patients with IAI have been included.
The current recommendations of the SIS regarding the treatment of patients with IAI are provided in this guideline.
外科感染学会（SIS）曾于1992年、2002年和2010年发布过关于腹腔内感染（IAI）管理的循证指南。在发布最新指南时，计划每五年更新一次指南，以确保建议的及时性和适当性。
基于先前的指南，工作组列出了一些与IAI患者治疗相关的主题，然后针对这些不同主题提出关键问题。所有问题都通过一般和特定的文献检索来处理，重点关注2008年以来发表的文章和其他信息。工作组全体成员或各个子组对2008年之前发表的这些出版物和其他材料进行了相关性审查，以确定与各个问题的相关性。通过反复达成共识的过程制定建议，所有工作组成员对每项建议进行投票，决定接受或拒绝。分级基于GRADE（推荐评估、制定和评价分级）系统；证据质量分为高、中或低，推荐强度分为强或弱。由不在工作组的SIS成员对文件进行审查。在对所有批评意见做出回应后，该文件由执行委员会批准为SIS的官方指南。
本指南总结了工作组目前针对IAI患者治疗制定的建议。已就个体患者的风险评估、源头控制、抗菌治疗的时机、选择和持续时间以及初始治疗失败患者的建议方法提出了循证建议。还纳入了与IAI儿科患者治疗相关的其他建议。
本指南提供了SIS目前关于IAI患者治疗的建议。
